More than 60 % patients of chronic kidney diseases (CKD) have hypertension. Control of blood pressure (BP) in CKD subjects is an important strategy

Size: px
Start display at page:

Download "More than 60 % patients of chronic kidney diseases (CKD) have hypertension. Control of blood pressure (BP) in CKD subjects is an important strategy"

Transcription

1

2 More than 60 % patients of chronic kidney diseases (CKD) have hypertension. Control of blood pressure (BP) in CKD subjects is an important strategy to reduce the burden of cardiovascular disease, the progression of CKD, development of end-stage renal disease (ESRD), and mortality.

3 Cardiovascular disease Osteoporosis Hypertension Diabetes Mellitus Ageing

4 From 30 to 40 years of age, the GFR generally (but not invariably) declines. In the older person, tubular and endocrine dysfunction in the kidney are common. Hypertension and chronic kidney disease in the elderly. Kithas PA, Supiano MA Adv Chronic Kidney Dis Jul; 17(4): The aging kidney. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG Kidney Int Sep; 74(6):

5 Showed that 37.8% of subjects >70 years had a GFR of <60 ml/min/1.73 m 2, this prevalence had increased from 27.8% in the NHANES data. Prevalence of chronic kidney disease in the United States.Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS JAMA Nov 7; 298(17): Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey ( ).Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ Arch Intern Med May 14; 161(9):

6 With greater access to health care among the elderly, this group is the fastest-growing population requiring dialysis, with 25% and 21.3% of dialysis patients in the United States and Australia, respectively, being 75 years of age and between 31 and 36% of patients receiving renal replacement therapy in different regions of the United Kingdom being >65 years of age.

7 Among NHANES III ( ) subjects aged 60 years of age, either treated or not treated for a high BP, there was a J-shaped relationship between BP and CKD prevalence. Thus, persons with a systolic BP of 120 to 159 mm Hg or a diastolic BP of 80 to 99 mm Hg had the lowest CKD prevalence, with a higher prevalence associated with a systolic BP <120 mm Hg or diastolic BP <80 mm Hg and a systolic BP 160 mm Hg or a diastolic BP 100 mm Hg.

8 Analyses of data NHANES, indicate that with increasing age, there is an increase in the prevalence and severity of CKD, confirming the strong relationship between BP and CKD in the elderly. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).Kalaitzidis R, Li S, Wang C, Chen SC, McCullough PA, Bakris GL Am J Kidney Dis Apr; 53(4 Suppl 4):S Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), Rao MV, Qiu Y, Wang C, Bakris G Am J Kidney Dis Apr; 51(4 Suppl 2):S30-7.

9 The elderly patients has thus been focused more on systolic than diastolic BP SHEP study In an analysis of 2181 persons >65 years of age in the placebo arm of this study, systolic BP was more predictive of decline in kidney function Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP).Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J J Am Soc Nephrol Nov; 13(11):

10 Arteriolar sclerosis, global glomerulosclerosis, and tubular atrophy are more common in the elderly. Although selection bias is likely, a kidney biopsy series of 413 patients aged 66 to 79 years and 100 patients aged 80 to 89 years showed nephrosclerosis in 34% of patients >80 years and in 7% of those 66 to 79 years. Renal vascular disease in the elderly.gómez Campderá FJ, Luño J, García de Vinuesa S, Valderrábano F Kidney Int Suppl Dec; 68:S73-7. Renal biopsy in patients aged 80 years and older.nair R, Bell JM, Walker PD Am J Kidney Dis Oct; 44(4):

11 Macrovascular disease is particularly common. This might influence BP targets or the preferred agents use to control BP, especially if heart failure, angina, cerebral vascular insufficiency, or peripheral vascular diseases are prominent.

12 Hypertension is a global health problem that contributes significantly to the cardiovascular and kidney disease morbidity and mortality of our aging population. In this context, it is clear that BP increases not only as we age but also as kidney function starts to decline.

13 A series of retrospective analyses of INVEST has further highlighted the issue of J-shaped relationships between systolic BP, diastolic BP and outcomes in elderly hypertensive patients with Coronary Artery Disease. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ Ann Intern Med Jun 20; 144(12): Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-Dehoff RM, Handberg EM, Champion A, Pepine CJ Am J Med Aug; 123(8): Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ JAMA Jul 7; 304(1):61-8.

14 The risk of all cause mortality and myocardial infarction, but not stroke, increased with reductions in diastolic BP in the patient group as a whole, all of whom had coronary arthery disease and were being treated for high BP. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ Ann Intern Med Jun 20; 144(12):

15 In patients aged 70 to 80 years, risk increased once systolic BP was less than 135 mm Hg or diastolic BP <75 mm Hg, while the risk increasing when systolic BP was <140 mm Hg or diastolic BP <70 mm Hg in patients 80 yrs. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-Dehoff RM, Handberg EM, Champion A, Pepine CJ Am J Med Aug; 123(8):

16 The Hypertension in the Very Elderly Trial (HYVET), involving patients 80 years of age or older, provided further assurance that BP lowering treatment of very elderly patients with a sustained BP of 160 mm Hg is beneficial. Treatment of hypertension in patients 80 years of age or older. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group N Engl J Med May 1; 358(18): Results of the pilot study for the Hypertension in the Very Elderly Trial. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L, Hypertension in the Very Elderly Trial Working Group J Hypertens Dec; 21(12):

17 Thus BP targets in the elderly, with or without CKD, should be set only after consideration of co-morbidities and should be achieved gradually. Based on the evidence on BP in the elderly (not selected for CKD), recent guidelines and consensus documents generally agree that <140/90 mm Hg should be the target in uncomplicated hypertension. National Clinical Guideline Center Hypertension. The Clinical Management of Primary Hypertension in Adults. Clinical Guideline 127Commissioned by the National Institute for Health and Clinical Excellence.2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ J Am Soc Hypertens Jul-Aug; 5(4):

18 A reasonable approach might be to use BP targets as recommended in the younger CKD population ( 140/90 mm Hg in non-albuminuric CKD and 130/80 mm Hg in albuminuric CKD), but to reach these targets gradually, bearing in mind that they may not be achievable without adverse effects particularly in a patient with multiple age-related co-morbidities. It is even more difficult to make recommendations in patients over 80 years of age with CKD due to the lack of evidence. Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney Int Suppl (2011) Dec; 2(5):

19 The most recent report from the panel members appointed to the Eighth Joint National Committee recommend a BP target of <150/90 mmhg for all adults aged 60 years and <140/90 mmhg for those aged <60 years evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). James PA, Oparil S, Carter BL, Cushman WC, Dennison- Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr., Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr., Narva AS, Ortiz E JAMA 2014; 311:

20 In the context of the aging patient with CKD, recent observational studies questioned the utility of lowering systolic BP (SBP) <130 mm Hg for all patients irrespective of age. Blood pressure and mortality in U.S. veterans with chronic kidney disease: A cohort study. Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K Ann Intern Med 2013;159:

21 The Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure in CKD work group recommends a target BP of 140/90 mmhg in those with CKD (both diabetic and nondiabetic) and urine albumin excretion <30 mg/24 h and suggests a target BP of 130/80 mmhg in those with CKD (both diabetic and nondiabetic) and urine albumin excretion >30 mg/24 h irrespective of age.

22 The KDIGO guidelines did not recommend a specific BP target for elderly persons with nondialysis-dependent CKD because of a lack of conclusive evidence.

23 The cohort included 21,015 adults, aged years, with an egfr<60 ml/min per 1.73 m 2 and hypertension defined using relevant International Classification of Diseases-9 codes, BP values obtained from the electronic health record, and antihypertensive therapy.

24 The authors modeled the relationship using multivariable Cox proportional hazards model that suggested among those aged years, a U-shaped association was noted between SBP and death, with the highest hazards for those with SBP<130 and >140 mmhg. Among those aged >70 years, SBP<130 mmhg was associated with a higher risk for death, but SBP>140 mmhg was not associated with death.

25 Data from a study of the Kidney Early Evaluation Program study suggest that the risk for CKD progression was higher among those with SBP=140 mmhg and highest among those with SBP 150 mmhg. KEEP Investigators: Blood pressure components and end-stage renal disease in persons with chronic kidney disease: The Kidney Early Evaluation Program (KEEP). Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M Arch Intern Med 2012; 172:

26 Similarly, findings from the Chronic Renal Insufficiency Cohort study (prospective longitudinal study) using time-updated data show that SBP>130 mmhg was more strongly associated with CKD progression. Chronic Renal Insufficiency Cohort Study Investigators: Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd., Rahman M, Steigerwalt S, Weir M, Wright JT Jr., Feldman HI Ann Intern Med 2015; 162:

27 Apart from age, per se, older adults with CKD suffer from electrolyte disorders, bone disease (metabolic bone disease and osteoporosis), and muscle atrophy predisposing them to falls and subsequent hospitalizations. There is significant concern for intense BP control and the risk for orthostatic hypotension and falls in this population. The risk of falls on initiation of antihypertensive drugs in the elderly. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. Osteoporos Int 2013; 24:

28 Veterans Affairs cohort, Kovesdy et al. reported that DBP of mmhg is associated with better survival. Weiss et al. provide new information by noting that patients with DBP<60 mmhg and >80 mmhg had higher risk for death irrespective of age. Systolic blood pressure and mortality in older adults with CKD. Weiss J, Peters D, Yang X, Petrik A, Smith D, Johnson E, Thorp M, Morris C, O Hare A Clin J Am Soc Nephrol 2015; 10:

29 SBP> mmhg is associated with higher mortality and higher incidence of Coronary Heart Disease, stroke, and ESRD in patients with CKD of all ages, but the strength of these associations diminishes with advanced age. DBP<70 mmhg is associated with higher mortality, but DBP shows no association with cardiovascular outcomes. Age and Outcomes Associated with BP in Patients with Incident CKD. Kovesdy CP, Alrifai A, Gosmanova EO, Lu JL, Canada RB, Wall BM, Hung AM, Molnar MZ, Kalantar-Zadeh K Clin J Am Soc Nephrol. 2016; May 6;11(5):

30 The SPRINT study showed that treating SBP to a target of <120 mmhg (with an overall achieved SBP of mmhg) versus <140 mmhg (with an achieved SBP of mmhg) resulted in significantly lower all-cause mortality rate and nominally lower composite cardiovascular event rate in patients with CKD. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT N Engl J Med 2015; 373:

31 These results support our findings regarding the lower risk of Coronary Heart Disease and stroke associated with lower SBP but may be discordant with the J-shaped mortality seen in our and other observational studies, even though we have only detected statistically significantly higher mortality for patients with SBP<110 mmhg.

32 SPRINT enrollees had markedly lower all-cause mortality rates compared with the populations examined in observational studies, which may be experiencing relatively more deaths unrelated to cardiovascular events. It is unclear whether they would derive a mortality benefit from SBP lowering to levels even stricter than those achieved in SPRINT.

33 The treatment of hypertension in younger patients with CKD toward targets recommended by current clinical guidelines is paramount to improve outcomes in these patients. In very elderly patients with CKD a more cautious BP-lowering strategy may be reasonable.

34

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

Recent Hypertension Guidelines

Recent Hypertension Guidelines Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH February 19, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National Committee

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines

2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines Measure Up/Pressure Down Response to the Release of 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National

More information

Aquifer Hypertension Guidelines Module

Aquifer Hypertension Guidelines Module Aquifer Hypertension Guidelines Module 2018 Aquifer Hypertension Guidelines Module 1 1. Introduction. In 2013 the National Heart Lung and Blood Institute (NHLBI) asked the American College of Cardiology

More information

Touyz, R. M., and Dominiczak, A. F. (2016) Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Hypertension, 67(4), pp. 688-689. There may be differences between this

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney International Supplements (2012) 2, ; doi: /kisup.2012.

Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney International Supplements (2012) 2, ; doi: /kisup.2012. http://www.kidney-international.org chapter 7 & 2012 KDIGO Chapter 7: Blood pressure management in elderly persons with CKD ND Kidney International Supplements (2012) 2, 377 381; doi:10.1038/kisup.2012.57

More information

Go low or no? Managing blood pressure in primary care. Hypertension is rarely an isolated risk factor

Go low or no? Managing blood pressure in primary care. Hypertension is rarely an isolated risk factor Cardiovascular system DEBATE Go low or no? Managing blood pressure in primary care There is much debate as to whether intensive blood pressure management, i.e. aiming for a systolic blood pressure less

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial [HYVET] R. Peters

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial [HYVET] R. Peters Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial [HYVET] R. Peters ClinicalTrials.gov: NCT00122811 Backgound The prevalence of dementia rises with increasing

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Blood Pressure Treatment Goals

Blood Pressure Treatment Goals Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Optimal blood pressure targets in chronic kidney disease

Optimal blood pressure targets in chronic kidney disease Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Unpacking Recent Hypertension Guidelines

Unpacking Recent Hypertension Guidelines Unpacking Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH August 21, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

Endorama. 5/7/15 Luke J. Laffin MD

Endorama. 5/7/15 Luke J. Laffin MD Endorama 5/7/15 Luke J. Laffin MD 58 year-old male with history of DM2, HTN, and CKD Presented to us in clinic in 7/2014 HTN since his 30s, DM2 and CKD for >10 years Multiple anti-hypertensives tried in

More information

The incidence and prevalence of hypertension

The incidence and prevalence of hypertension Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Weber, M. A., Poulter, N. R., Schutte, A. E., Burrell, L. M., Horiuchi, M., Prabhakaran, D., Ramirez, A. J., Wang, J.-G., Schiffrin, E. L., and Touyz, R. (2016) Is it time to reappraise blood pressure

More information

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016 Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34

More information

SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section

SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section Editors) What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease? Gopesh K. Modi, MD DM 1,

More information

Antihypertensive Therapy in Kidney Disease. Association of Antihypertensive Therapy and Diastolic Hypotension in Chronic Kidney Disease

Antihypertensive Therapy in Kidney Disease. Association of Antihypertensive Therapy and Diastolic Hypotension in Chronic Kidney Disease Antihypertensive Therapy in Kidney Disease Association of Antihypertensive Therapy and Diastolic Hypotension in Chronic Kidney Disease Carmen A. Peralta, Michael G. Shlipak, Christina Wassel-Fyr, Hayden

More information

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression

More information

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

Blood Pressure Indexes and End-Stage Renal Disease Risk in Adults With Chronic Kidney Disease

Blood Pressure Indexes and End-Stage Renal Disease Risk in Adults With Chronic Kidney Disease Blood Pressure Indexes and End-Stage Renal Disease Risk in Adults With Chronic Kidney Disease William McClellan, Emory University EK Bell L Gao S Judd SP Glasser OM Gutiérrez M Safford DT Lackland DG Warnock

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials

Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials THERAPEUTIC IMPLICATION 10.5005/jp-journals-10043-0055 Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials 1 Prakash Deedwania, 2 Tushar Acharya abstract

More information

2017 High Blood Pressure Clinical Practice Guideline

2017 High Blood Pressure Clinical Practice Guideline 2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

SPRINT: Consequences for CKD patients

SPRINT: Consequences for CKD patients SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES

More information

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012 How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D.,

More information

Status Report on the NHLBI-Sponsored CVD Prevention Guidelines

Status Report on the NHLBI-Sponsored CVD Prevention Guidelines Status Report on the NHLBI-Sponsored CVD Prevention Guidelines HIGH BLOOD PRESSURE Paul A. James, M.D. Roy J. and Lucille A. Carver College of Medicine The University of Iowa Iowa City IA NHLBI Adult CVD

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Classification of CKD by Diagnosis

Classification of CKD by Diagnosis Classification of CKD by Diagnosis Diabetic Kidney Disease Glomerular diseases (autoimmune diseases, systemic infections, drugs, neoplasia) Vascular diseases (renal artery disease, hypertension, microangiopathy)

More information

In late 2017, the American College of Cardiology (ACC)

In late 2017, the American College of Cardiology (ACC) SPECIAL ARTICLE The 2017 U.S. Hypertension Guidelines: What Is Important for Older Adults? William C. Cushman, MD,* and Karen C. Johnson, MD, MPH In late 2017, the American College of Cardiology (ACC)

More information

When should blood pressure be lowered? Should treatment be guided by blood pressure values or total cardiovascular risk?

When should blood pressure be lowered? Should treatment be guided by blood pressure values or total cardiovascular risk? OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Editorial J Hypertens Res (2016) 2(2):47 51 When should blood pressure be lowered? Should treatment be guided

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

12.2. Structured, Team-Based Care Interventions for Hypertension Control

12.2. Structured, Team-Based Care Interventions for Hypertension Control Downloaded from http://hyper.ahajournals.org/ by guest on November 13, 2017 12.2. Structured, Team-Based Care Interventions for Hypertension Control Recommendation for Structured, Team-Based Care Interventions

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01. NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic

More information

Long-term outcomes in nondiabetic chronic kidney disease

Long-term outcomes in nondiabetic chronic kidney disease original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

KDIGO Controversies Conference on Blood Pressure in CKD

KDIGO Controversies Conference on Blood Pressure in CKD KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve

More information

Interpreting SPRINT: How low should you go?

Interpreting SPRINT: How low should you go? INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will engage their patients in a shared decision-making process regarding intensive lowering of blood pressure, with discussion of the benefits

More information

Blood pressure treatment target in diabetes. Should it be <130 mmhg?

Blood pressure treatment target in diabetes. Should it be <130 mmhg? Blood pressure treatment target in diabetes Should it be

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

Screening and treatment of hypertension in older adults: less is more?

Screening and treatment of hypertension in older adults: less is more? WENNBERG INTERNATIONAL COLLABORATIVE SPRING POLICY MEETING 2018 Zürich, April 12th Screening and treatment of hypertension in older adults: less is more? Daniela Anker (1), Brigitte Santos-Eggimann (2),

More information

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016

Hypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016 Hypertension targets in the elderly Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016 NICE (2011) Aim for a target clinic blood pressure below 150/90 mmhg in people aged 80

More information

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division

More information

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP

More information

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0 Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National

More information

Hypertension is an important global public

Hypertension is an important global public IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual

More information

Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly

Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2015 Hypertension Management: Making Sense of Guidelines and Therapy

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD

Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD

More information

ABSTRACT. Special Communication February 5, 2014

ABSTRACT. Special Communication February 5, 2014 Page 1 of 20 Special Communication February 5, 2014 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National

More information

Management of Hypertension: JNC 8 and Beyond

Management of Hypertension: JNC 8 and Beyond Cardiovascular Innovations and Applications Vol. 1 No. 4 (2016) 409 416 ISSN 2009-8618 DOI 10.15212/CVIA.2016.0030 REVIEW Management of Hypertension: JNC 8 and Beyond Ezra A. Amsterdam, MD 1, Sandhya Venugopal,

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Disclosure. Objectives. Which Target to Target? A Blood Pressure Goal Update

Disclosure. Objectives. Which Target to Target? A Blood Pressure Goal Update Which Target to Target? A Blood Pressure Goal Update Portia N. Davis, Pharm.D. Assistant Professor of Pharmacy Practice Texas Southern University College of Pharmacy & Health Sciences Disclosure I have

More information

Interventions to reduce progression of CKD what is the evidence? John Feehally

Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think

More information

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD

Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly

More information

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table

More information

Firenze 22 settembre 2007

Firenze 22 settembre 2007 Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non

More information

DECLARATION OF CONFLICT OF INTEREST. None

DECLARATION OF CONFLICT OF INTEREST. None DECLARATION OF CONFLICT OF INTEREST None How low should we go to avoid harm in hypertensives with comorbidities? CORONARY ARTERY DISEASE Prof. Dr. Maria DOROBANTU, FESC,FACC CARDIOLOGY EMERGENCY HOSPITAL

More information

Chapter 5: Acute Kidney Injury

Chapter 5: Acute Kidney Injury Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

The Seventh Report of the Joint National Commission

The Seventh Report of the Joint National Commission The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,

More information

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

TREATMENT OF GERIATRIC HYPERTENSION: THE SPRINT TRIAL AND RECENT GUIDELINES

TREATMENT OF GERIATRIC HYPERTENSION: THE SPRINT TRIAL AND RECENT GUIDELINES Treatment of Geriatric Hypertension: the SPRINT Trial and the Evolving Systolic Blood Pressure Target TREATMENT OF GERIATRIC HYPERTENSION: THE SPRINT TRIAL AND RECENT GUIDELINES MARK A. SUPIANO, M.D. PROFESSOR

More information

Potential U.S. Population Impact of the 2017 American College of Cardiology/ American Heart Association High Blood Pressure Guideline

Potential U.S. Population Impact of the 2017 American College of Cardiology/ American Heart Association High Blood Pressure Guideline Accepted Manuscript Potential U.S. Population Impact of the 2017 American College of Cardiology/ American Heart Association High Blood Pressure Guideline Paul Muntner, PhD, Robert M. Carey, MD, Samuel

More information

2782 Diabetes Care Volume 37, October 2014

2782 Diabetes Care Volume 37, October 2014 2782 Diabetes Care Volume 37, October 2014 Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT) Diabetes Care 2014;37:2782 2788 DOI: 10.2337/dc14-0284

More information

Chapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,

Chapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University, Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information